The Claim
In non-obese adults with type 2 diabetes and visceral adiposity, daily administration of ipragliflozin 50 mg for 12 weeks is associated with a median reduction in epicardial fat volume from 102 cm³ to 89 cm³, suggesting a potential link between SGLT2 inhibition and reduced pericardial fat accumulation independent of overall obesity.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In non-obese adults with type 2 diabetes and excess abdominal fat, taking ipragliflozin 50 mg daily for 12 weeks is associated with a reduction in epicardial fat volume from 102 cm³ to 89 cm³.
See the scientific wording
In non-obese adults with type 2 diabetes and visceral adiposity, daily administration of ipragliflozin 50 mg for 12 weeks is associated with a median reduction in epicardial fat volume from 102 cm³ to 89 cm³, suggesting a potential link between SGLT2 inhibition and reduced pericardial fat accumulation independent of overall obesity.
The drug blocks sugar reabsorption in the kidneys, causing sugar to leave the body in urine. This lowers blood sugar and insulin levels, which stops the body from storing fat in and around the heart. Instead, the body starts burning fat for energy, reducing the fat layer around the heart.
What the research says
1 studyIn people with type 2 diabetes who aren't overweight but have extra belly fat, taking a specific diabetes drug called ipragliflozin for 12 weeks lowered the amount of fat around their heart—even though their overall weight didn't drop much. This suggests the drug might directly help reduce heart fat.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.